

Review Article

Effect of Probiotics as Therapeutical and Preventive Modality for Atopic Dermatitis; Lessons from Clinical Trials

William Suciangto ¹, Nada Indira Ramadhani Nasrum ¹

¹ Faculty of Medicine , Hasanuddin University, Makassar, Indonesia

Corresponding Author:

Name: William Suciangto

Email: williamsuciangto@gmail.com

ARTICLE INFO

Keywords:

probiotics, atopic dermatitis, inflammation

How to cite:

Suciangto, W. and Nasrum, N. I. R. (2024). Effect of Probiotics as Therapeutical and Preventive Modality for Atopic Dermatitis; Lessons from Clinical Trials. *Nusantara Medical Science Journal*, 9(1), 48–57.

DOI:

10.20956/nmsj.vi.20734

ABSTRACT

Introduction: Atopic dermatitis is a chronic relapsing inflammatory skin disease that can significantly impact patients' quality of life. Current therapy for atopic dermatitis is corticosteroids, calcineurin inhibitors, and immunosuppressants, but the recurrence of this disease is still reported, and their long-term use is vicious due to their immunosuppressive side effects; the need to discover a new modality that can be used as a therapeutical and preventive modality for atopic dermatitis. Probiotics have been well known for decades due to their various biological activities, including anti-inflammatory and immune-regulatory activity, that have many potential benefits for some skin diseases, including atopic dermatitis. **Method:** The method consisted of analyzing and evaluating relevant journal literature published within the past ten years. **Result:** Several clinical trials have proven the effectiveness of various species of Lactobacilli in improving clinical outcomes for children with atopic dermatitis. Clinical improvement of atopic dermatitis in children can be achieved not only through the administration of a single probiotic but also by combining different probiotic species. **Conclusions:** Based on those studies, probiotics are the potential therapeutical and preventive modality for atopic dermatitis and its primary possible mechanism.

Copyright © 2024 NMSJ. All rights reserved.

1. INTRODUCTION

Atopic Dermatitis is a chronic relapsing inflammatory skin disease with a frequently remitting and relapsing course, which manifests as eczema and pruritus and is mostly found in persons with atopic predisposition.^{1,2} There are about 15-20% children and 1-3% adults live with atopic dermatitis around the world³. In Indonesia, atopic dermatitis is one of the top ten children's skin diseases and has affected 611 (23,67%) children.⁴

Atopic dermatitis can cause life quality impairment due to its symptoms such as erythematous eczema, crusting, lichenification, excoriation, exudation, and itching, that vary from mild and localized lesions, into severe and widespread lesions, leading to physical appearance disturbances which can follow by mental disorders, including decreased self-esteem, attention deficit, sleep disturbances, headache, hyperactivity, disturbed social life, and increased suicidal ideas.^{2,3,5} In addition, serious emergency complications such as eczema herpeticum can also occur in untreated atopic dermatitis cases, resulting in severe sequelae of the eyes and meninx.⁶

The chronicity and recurrence of atopic dermatitis bring the importance of enlarging an effective therapeutic modality in controlling the symptoms and preventing the recurrence to enhance the quality of life for the patients.^{1,2} Probiotics are non-pathogenic live microorganisms from various genera and species that has many advantages. Probiotics have been well-known and utilized for decades to treat several health problems, including diarrhea, infectious intestinal disease, and some inflammatory conditions such as inflammatory bowel disease and even atopic dermatitis.⁷ Recently, the gut-skin axis has been discovered as a new potential approach for preventing and treating several skin diseases due to some similarity between the gut and the skin, providing the possible mechanism of probiotics benefit in treating several inflammatory skin diseases, including atopic dermatitis.⁸ This review aims to provide clinical evidence of probiotics' therapeutical and preventive effects for atopic dermatitis and its immunoregulatory mechanism.

2. IMMUNOPATHOGENESIS OF ATOPIC DERMATITIS

Atopic dermatitis occurs due to a complex interplay of multiple factors, including genetics, skin barrier, skin microbiome, environment, neuroimmunology, and immune dysregulation. Cutaneous inflammation is a significant factor that plays a crucial role in the pathogenesis of atopic dermatitis.^{9,10} Dysregulated T-Helper-2 (Th2) will produce abundant pro-inflammatory cytokines such as IL-4, IL-5, and IL-13, influencing chemokine production, skin barrier dysfunction, antimicrobial peptides suppression, and inflammation. A combination of epidermal barrier dysfunction and environmental factors will stimulate the keratinocytes to produce IL-1 β , IL-25, IL-33, Macrophage-Derived Chemokine (MDC), Thymus and Activation-Regulated Chemokine (TARC), and Thymic Stromal Lymphopoietin (TSLP), leading to activation of dendritic and Langerhans cells. After being activated, dendritic and Langerhans cells stimulate Th2 cells to produce IL-4, IL-5, IL-13, and IL-33, resulting in an alteration of keratinocytes proliferation, suppressed production of antimicrobial peptides (AMP) and increased inflammatory reaction. Th2-derived IL-5 will also drive the differentiation of B lymphocytes into IgE, while IL-4 and IL-13 together will activate eosinophil and trigger it to be degranulated, causing an itchy sensation in the patients. Conversely, Th2 can also induce pruritus by secreting IL-31, which produces brain-derived natriuretic peptides. Meanwhile, in chronic

atopic dermatitis, there are high amounts of Th17, Th22, and Th1, which produce IL-17, IL-22, and Interferon- γ (IFN- γ) that contribute to abnormal keratinocyte proliferation and differentiation and increased keratinocyte apoptosis.⁹⁻¹²




Fig 1. Immuno-pathogenesis of atopic dermatitis^{1,9-12}

3. CLINICAL IMPROVEMENT OF ATOPIC DERMATITIS WITH PROBIOTICS SUPPLEMENTATION

Several clinical studies were conducted to determine probiotics' effect in improving patients' clinical conditions with atopic dermatitis. Various species of microbiota were involved in the clinical trials, but Bifidobacteria and Lactobacilli were the two most common bacteria used in the experiments.¹³⁻²⁸

Several clinical trials have proven the effectiveness of various species of Lactobacilli in improving clinical outcomes for children with atopic dermatitis.^{13,14,21-25} In a study by Niccoli et al., it was found that administration of Lactobacillus salivarius (L. salivarius) LS01 to 43 children with atopic dermatitis aged 0-11 years for 16 weeks was effective in improving the clinical symptoms of atopic dermatitis, indicated by reduced Scoring of Atopic Dermatitis (SCORAD) and itch index.¹³ Significant clinical outcomes were also found by L. plantarum supplementation for atopic dermatitis children compared to placebo in two randomized double-blinded placebo-controlled trials by Han et al., and Prakoeswara et al.^{14,21} Two clinical experiments revealed the ability of L. rhamnosus in providing better clinical outcome for children with atopic dermatitis.^{22,23} In a randomized, double-masked placebo-controlled trial by Wu et al., therapy with L. rhamnosus for 8 weeks was found to demote SCORAD score more significantly compared to the placebo group, followed by more considerable decrease in surface area, intensity, and subjective symptoms in the L. rhamnosus group.²² Jeong et al. also observed a significantly more remarkable change in SCORAD total score ($p=0.0283$) in the children who were given oral L. rhamnosus at week 12 compared to the placebo group.²³ Another randomized,

double-blind, placebo-controlled trial was performed by Yan et al. to evaluate the benefit of *L. paracasei* supplementation for infancy atopic dermatitis. The result showed a more remarkable change in SCORAD value in the *L. paracasei* group than in the placebo group in the 16th week of the treatment.²⁴ Ahn et al. also performed a randomized double-blinded placebo-controlled study in order to investigate the effect of treatment with *L. pentosus* on pediatric atopic dermatitis and found significantly better clinical outcomes, which were evidenced by significantly lower SCORAD value in the children receiving *L. pentosus* compared to the group that receiving placebo.²⁵

Clinical improvement of atopic dermatitis in children can be achieved not only through the administration of a single probiotic but also by combining different probiotic species.^{26–28} The effect of *L. paracasei* and *L. fermentum* combination in atopic dermatitis was studied by Wang et al. in a randomized, prospective, double-blind, placebo-controlled trial which showed lower SCORAD and DLQI value in the group that received probiotics than in the group that received placebo, indicating the better clinical outcome achieved by supplementation of the combination probiotics.²⁶ The Benefit of another mixture of Lactobacilli for atopic dermatitis children was studied by Cukrowska et al. in a multicenter randomized, double-blind placebo-controlled study where atopic dermatitis children under 2 years old with SCORAD scores more than ten were randomized into the probiotic group and placebo group. The probiotic group received a combination of *L. rhamnosus* and *L. casei*, while the placebo group was given maltodextrin. The study result showed a higher reduction in SCORAD score from the baseline in the probiotic group compared to the placebo group. The number of participants who showed clinical improvement during the third month of intervention and the ninth month of follow-up was also higher in the probiotic group than in the placebo group.²⁸ Meanwhile, clinical improvement in children with atopic dermatitis was also observed in combination therapy between *Bifidobacterium lactis* (*B. lactis*), *B. longum*, and *L. casei*. Lopez et al. conducted a randomized, double-masked placebo-controlled trial where the children from the probiotic group were treated with an oral combination of *B. lactis*, *B. longum*, and *L. casei* for 12 weeks, while the placebo group was given maltodextrin orally. By the end of the study, the probiotic group exhibited a significantly greater reduction in the SCORAD index.²⁷

The clinical benefits of probiotics for atopic dermatitis were also studied in the adult population.^{15–17} In A randomized, double-blind, placebo-controlled trial conducted by Drago et al., administering *L. salivarius* LS01 twice daily for 16 weeks reduced the SCORAD value significantly ($p < 0.001$) compared to the placebo.¹⁵ Better clinical outcome of atopic dermatitis adults was also found with the treatment of other Lactobacillus in a study by Inoue et al. A total of 49 adults with atopic dermatitis were randomized into two groups, L-92 group treated with *L. acidophilus* L-92, and placebo group that given maltose, starch, vegetable oil, and fat. The study was performed for 8 weeks. At the end of the study, the significant change ($p < 0.01$) of SCORAD and its components, including the subjective symptoms, eczema intensity, and area, was reported in the L-92 group. A more significant proportion of respondents that achieved clinical improvement was found in the L-92 group (70.8%) compared to the placebo (44%).¹⁶ Besides Lactobacilli, better clinical outcome for adults with atopic dermatitis was also reported with probiotic therapy with *Bifidobacterium animalis subs lactis* in a multicenter randomized, double-blind, placebo-controlled study by Matsumoto et al. At

the end of the study, in the 8th week, a significantly better clinical outcome ($p < 0.05$) was reported from the probiotic group, including improvement of itch, hurt sensation, sensitive skin symptoms, and tiredness.¹⁷

Clinical improvement of adults with atopic dermatitis was also reported in several clinical trials using a combination of probiotics species.¹⁸⁻²⁰ In a randomized, double-blind, placebo-controlled study by Lemoli et al., the clinical improvement of adults with atopic dermatitis was exhibited by a significant reduction of SCORAD index ($p < 0.001$) and DLQI ($p = 0.024$) in the group that ingested a combination of *L. salivarius* LS01 and *B. breve* BR03 compared to the placebo group.¹⁸ Another probiotic therapy with *L. plantarum* and *B. bifidum* probiotics was also found to improve the clinical symptoms of adults with atopic dermatitis. Some patients treated with the probiotics experienced a decreased SCORAD index compared to the placebo and oligose group.¹⁹ In a separate clinical study, Drago et al. observed improved clinical outcomes in adults with atopic dermatitis following a one-month treatment with a combination of *Lactobacillus salivarius* LS01 and *Streptococcus thermophilus* ST10. This improvement was evidenced by a significantly reduced SCORAD index ($p < 0.0001$) compared to the placebo group.²⁰

4. PROBIOTICS AS PREVENTIVE MODALITY FOR ATOPIC DERMATITIS

Several studies have explored the ability of probiotics to prevent atopic dermatitis, as well as their ability to improve the clinical outcome of atopic dermatitis, especially in the pediatric population.²⁹⁻³¹ In a randomized controlled trial, Wickens et al. revealed that administration of either *L. rhamnosus* HN001 or *B. animalis* subsp *lactis* from 35 weeks gestation until 2 years of the infants age was successful to lower the risk of atopic eczema at age of 4 years in the high-risk infants (27.1% in *L. rhamnosus* group and 33.3% in *B. animalis* subsp *lactis* group) compared to placebo group (39.3%).²⁹ *Bifidobacterium* also exhibited a protective effect against atopic dermatitis development. In a clinical study by Enomoto et al., supplementation of *B. longum* BB536 and *B. breve* M-16V combination from 4 weeks before the expected delivery until the first sixth month of the infants was able to reduce the occurrence of atopic dermatitis significantly ($p = 0.033$) compared to placebo.³⁰ Another clinical trial by Marlow et al. also found that *L. rhamnosus* HN001 and *B. animalis* subsp *lactis* HN019 were able to reduce the risk of atopic dermatitis. However, *L. rhamnosus* exhibited a major reduction compared to *B. animalis* subsp *lactis*.³¹

5. IMMUNOREGULATORY EFFECTS OF PROBIOTICS IN ATOPIC DERMATITIS

Atopic dermatitis occurs due to various immune dysregulation involving variable types of leucocytes with their inflammatory cytokines and mediators, both in the acute and chronic phases of the disease. Th2 plays a significant role in the acute phase of atopic dermatitis. Dysfunction of the skin barrier and several environmental triggering factors will provoke the production of certain mediators from epithelial cells that will trigger the dendritic cell to activate the Th2. Various cytokines, including IL-4, IL-5, and IL-13, are then secreted by activated Th2, leading to impaired differentiation of keratinocytes, reduced antimicrobial peptides, and itching.^{1,9,10} Several clinical trials have revealed probiotics' ability to regulate Th2-related pro-inflammatory cytokines in the acute phase of atopic dermatitis.^{16,19,21,26,32} In a randomized placebo-controlled trial by Wang et al., serum IL-4 levels were found to be reduced after 3 months of treatment with

Lactobacillus plantarum and *Lactobacillus fermentum*.²⁶ Another randomized placebo-control study conducted by Fang et al also found downregulation of IL-4 and IL-13 by oral treatment with *B. bifidum* or *L. plantarum*.¹⁹ Decreased levels of IL-4 were also observed after 12 weeks of therapy with *L. plantarum* alone in several randomized, double-masked, placebo-controlled studies.^{21,32} Meanwhile, Inoue et al. also stated the ability of *L. acidophilus* L-92 to downregulate IL-4 in a randomized, double-blind, placebo-controlled study of adults with atopic dermatitis.¹⁶

In the chronic phase of atopic dermatitis, Th17, Th22, and Th1, together with the cytokines they produce, play a pivotal role in modulating the abnormality of keratinocytes. Th17 and Th22 will release IL-17 and IL-22, which contribute to abnormal proliferation and differentiation of the keratinocytes, while Th1 secretes IFN- γ , leading to apoptosis of the keratinocytes.^{1,9,10} Some species of probiotics were found to attenuate certain T-helper and cytokines, which is crucial in the chronic phase of atopic dermatitis. In a randomized placebo-controlled trial by Ro et al., a reduced proportion of Th22 was found in the group that received a combination of *L. rhamnosus*, *B. animalis* subsp *lactis*, and *L. acidophilus* compared to the placebo.³³ Meanwhile, the level of IFN- γ that plays a role in the chronic phase of atopic dermatitis produced by Th1 and is responsible for keratinocyte apoptosis is significantly reduced after administration of *L. plantarum* in two randomized, double-blind placebo-controlled studies by either Prakoeswara et al. ($p=0.006$) and Han et al. ($p<0.01$).^{21,32} Reduced proportion and activity of several T-cells subsets related to the chronic phase of atopic dermatitis can be linked to the finding that shows the increased T-regulatory cell in cases of probiotics supplementation of *L. salivarius* and *B. breve* in a clinical study conducted by Lemoli et al.¹⁸ Besides controlling inflammation by downregulating specific pro-inflammatory cells and cytokines; probiotics was also discovered to upregulate IL-10 which is an anti-inflammatory cytokine, as well as found by Fang et al. in a clinical study using *B. bifidum* and *L. plantarum*.¹⁹

Pruritus is a prominent feature of atopic dermatitis, and it is associated with impaired quality of life due to sleep disturbances, attention deficit, and hyperactivity.³ Several pathways are related to cause itching in atopic dermatitis. The release of IL-5 from Th2 will lead to activation of eosinophil. Meanwhile, IL-4 and IL-13 produced by Th2 will promote B-lymphocyte differentiation into IgE. Increased levels of eosinophil and IgE and the Th2-type cytokines trigger an itchy sensation in atopic dermatitis.⁹⁻¹² Several clinical studies have discovered the capability of some species of probiotics to regulate eosinophil and IgE in atopic dermatitis patients.^{16,17,21,23,32} In the randomized, double-masked, placebo-controlled trial by Han et al., a significantly lower eosinophil count was detected after 12 weeks of therapy with *L. plantarum*.³² The suppressing effect of eosinophil was also found in another species of *Lactobacillus*. Jeong et al. explored the effect of *L. rhamnosus* on eosinophil in atopic dermatitis patients in a randomized, double-blind, placebo-controlled study, where 12 weeks of administration of *L. rhamnosus* was able to decrease the eosinophil count.²³ Furthermore, Prakoeswara et al. also found a decreased IgE with 12 weeks of supplementation of *L. plantarum*.²¹ In another study by Inoue et al., lower IgE was also observed by oral administration of *L. acidophilus* for 8 weeks.¹⁶ In addition, another antipruritic mechanism of probiotics in atopic dermatitis was also discovered by Matsumoto et al., which shows the ability of the oral administration of *B. animalis* subsp *lactis* to increase the levels of kynurenic acid, an antipruritic and antinociceptive metabolite.¹⁷

Table 1. Clinical and Immunoregulatory Benefits of Various Probiotics Species for Atopic Dermatitis

Probiotics Species	Outcome	Population	References
<i>L. salivarius</i>	Reduced SCORAD	Children	Niccoli et al ¹³
	Reduced Itch Index	Adult	Drago et al ¹⁵
<i>L. plantarum</i>	Reduced SCORAD, Lower IFN- γ , Lower IL-4	Children	Niccoli et al ¹³
	Decreased eosinophil	Children	Han et al ¹⁴ , Prakoeswara et al ²¹
	Reduced IgE	Children	Han et al ¹⁴
<i>L. acidophilus</i>	Reduced SCORAD; improvement of subjective symptoms, eczema intensity and area; lower IL-4 and IgE	Adult	Prakoeswara et al ²¹
<i>L. rhamnosus</i>	Reduced SCORAD	Adult	Inoue et al ¹⁶
	Reduced eosinophil	Children	Wu et al ²² , Jeong et al ²³
	Decreased risk of atopic eczema	Children	Jeong et al ²³ , Wickens et al ²⁹
<i>L. paracasei</i>	Reduced SCORAD	Infant	Yan et al ²⁴
<i>L. pentosus</i>	Reduced SCORAD	Children	Ahn et al ²⁵
<i>B. animalis subsp. lactis</i>	Improvement of itchy and hurt sensation, sensitive skin symptoms, and tiredness; increased anti-pruritic substance (kynurenic acid)	Adult	Matsumoto et al ¹⁷
<i>L. salivarius</i> and <i>B. breve</i>	Reduced SCORAD, DLQI, and increased T-Regulatory cell	Adult	Iemoli et al ¹⁸
<i>L. salivarius</i> and <i>S. thermophilus</i>	Reduced SCORAD	Adult	Drago et al ²⁰
<i>L. paracasei</i> and <i>L. fermentum</i>	Reduced SCORAD, DLQI, Decreased IL-4 and IgE	Children	Wang et al ²⁶
<i>B. lactis</i> , <i>B. longum</i> , and <i>L. casei</i>	Reduced SCORAD	Children	Lopez et al ²⁷
<i>B. bifidum</i> or <i>L. plantarum</i>	Reduced SCORAD, Lower IL-4 and IL-13, and Increased IL-10	Adult	Fang et al ¹⁹
<i>L. casei</i> and <i>L. rhamnosus</i>	Reduced SCORAD	Children	Cukrowska et al ²⁸
<i>B. longum</i> and <i>B. breve</i>	Decreased occurrence of atopic dermatitis	Children	Enomoto et al ³⁰
<i>L. rhamnosus</i> or <i>B. animalis subsp lactis</i>	Decreased the risk of atopic dermatitis	Children	Marlow et al ³¹
<i>L. rhamnosus</i> and <i>B. animalis subsp lactis</i>	Lower Th22 cell	Infant	RØ et al ³³

6. CONCLUSION

Probiotics, with their various species, effectively improve the clinical outcomes for patients with atopic dermatitis, both in pediatric and adult populations. Besides improving the clinical symptoms, probiotics can also prevent the occurrence of atopic dermatitis, especially in pediatric patients. Clinical improvement and preventive properties of probiotics in atopic dermatitis were supported by their ability to regulate several leucocytes and their cytokines that play essential roles in atopic dermatitis, including Th22, eosinophil, IgE, IL-4, IL-13, and IFN- γ . Probiotics can be used as a therapeutical approach to improve the clinical outcomes for atopic dermatitis patients and even prevent

the occurrence of atopic dermatitis in high-risk populations. Further research is still needed to determine the best species and combination of probiotics for treating atopic dermatitis.

REFERENCES

1. Katayama I, Aihara M, Ohya Y, Saeki H, Shimojo N, Shoji S, et al. Japanese guidelines for atopic dermatitis 2017. *Allergol Int* [Internet]. 2017;66(2):230–47. Available from: <http://dx.doi.org/10.1016/j.alit.2016.12.003>
2. Waldman AR, Ahluwalia J, Udkoff J, Borok JF, Eichenfield LF. Atopic dermatitis. *Pediatr Rev*. 2018;39(4):180–93.
3. Avena-Woods C. Overview of atopic dermatitis. *Am J Manag Care*. 2017;23(8):S115–23.
4. Keles FF, Pandaleke HEJ, Mawu FO. Profil dermatitis atopik pada anak di Poliklinik Kulit dan Kelamin RSUP Prof. Dr. R. D. Kandou Manado periode Januari 2013 – Desember 2015. *e-CliniC*. 2016;4(2).
5. Sidbury R, Kodama S. Atopic dermatitis guidelines: Diagnosis, systemic therapy, and adjunctive care. *Clin Dermatol* [Internet]. 2018;36(5):648–52. Available from: <https://doi.org/10.1016/j.clindermatol.2018.05.008>
6. Page SS, Weston S, Loh R. Atopic dermatitis in children. *Aust Fam Physician*. 2016;45(5):293–6.
7. Islam SU. Clinical Uses of Probiotics. *Medicine (Baltimore)*. 2016;95(5):e2658.
8. Fang Z, Li L, Zhang H, Zhao J, Lu W, Chen W. Gut Microbiota, Probiotics, and Their Interactions in Prevention and Treatment of Atopic Dermatitis: A Review. *Front Immunol*. 2021;12(July):1–13.
9. Boothe WD, Tarbox JA, Tarbox MB. Atopic Dermatitis : Pathophysiology. :21–37.
10. Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. *Allergy Asthma Proc*. 2019;40(2):84–92.
11. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. *Lancet* [Internet]. 2020;396(10247):345–60. Available from: [http://dx.doi.org/10.1016/S0140-6736\(20\)31286-1](http://dx.doi.org/10.1016/S0140-6736(20)31286-1)
12. Nakahara T, Kido-Nakahara M, Tsuji G, Furue M. Basics and recent advances in the pathophysiology of atopic dermatitis. *J Dermatol*. 2021;48(2):130–9.
13. Niccoli AA, Artesi AL, Candio F, Ceccarelli S, Cozzali R, Ferraro L, et al. Preliminary results on clinical effects of probiotic *Lactobacillus salivarius* LS01 in children affected by atopic dermatitis. *J Clin Gastroenterol*. 2014;48(February 2013):S34–6.
14. Han Y, Kim B, Ban J, Lee J, Kim BJ, Sun B, et al. SKIN AND EYE DISEASE A randomized trial of *Lactobacillus plantarum* CJLP133 for the treatment of atopic dermatitis. 2012;23:667–73.
15. Drago L, Toscano M, De Vecchi E, Piconi S, Iemoli E. Changing of fecal flora and clinical Effect of *L. salivarius* LS01 in adults with atopic dermatitis. *J Clin Gastroenterol*. 2012;46(SUPPL. 1):56–63.
16. Inoue Y, Kambara T, Murata N, Komori-Yamaguchi J, Matsukura S, Takahashi Y, et al. Effects of oral administration of *Lactobacillus acidophilus* I-92 on the symptoms and serum cytokines of atopic dermatitis in Japanese adults: A double-blind, randomized, clinical trial. *Int Arch Allergy Immunol*. 2014;165(4):247–54.
17. Matsumoto M, Ebata T, Hirooka J, Hosoya R, Inoue N, Itami S, et al. Antipruritic effects of the probiotic strain LKM512 in adults with atopic dermatitis. *Ann Allergy, Asthma Immunol* [Internet]. 2014; Available from: <http://dx.doi.org/10.1016/j.anai.2014.05.002>
18. Enrico Iemoli, Daria Trabattoni, Serena Parisotto, Linda Borgonovo, Marco Toscano, Giuliano Rizzardini, Mario Clerici, Elena Ricci, Alessandra Fusi, Elena

- De Vecchi, Stefania Piconi and LD. Probiotics reduce gut microbial translocation and improve adult atopic dermatitis. *J Clin Gastroenterol.* 2012;46(1):33–40.
19. Fang Z, Lu W, Zhao J, Zhang H, Qian L, Wang Q, et al. Probiotics modulate the gut microbiota composition and immune responses in patients with atopic dermatitis: a pilot study. *Eur J Nutr [Internet].* 2020;59(5):2119–30. Available from: <https://doi.org/10.1007/s00394-019-02061-x>
 20. Drago L, De Vecchi E, Toscano M, Vassena C, Altomare G, Pigatto P. Treatment of atopic dermatitis eczema with a high concentration of *Lactobacillus salivarius* LS01 associated with an innovative gelling complex a pilot study on adults. *J Clin Gastroenterol.* 2014;48(December):S47–51.
 21. Prakoeswa CRS, Herwanto N, Prameswari R, Astari L, Sawitri S, Hidayati AN, et al. *Lactobacillus plantarum* IS-10506 supplementation reduced SCORAD in children with atopic dermatitis. *Benef Microbes.* 2017;8(5):833–40.
 22. Wu YJ, Wu WF, Hung CW, Ku MS, Liao PF, Sun HL, et al. Evaluation of efficacy and safety of *Lactobacillus rhamnosus* in children aged 4–48 months with atopic dermatitis: An 8-week, double-blind, randomized, placebo-controlled study. *J Microbiol Immunol Infect [Internet].* 2017;50(5):684–92. Available from: <https://doi.org/10.1016/j.jmii.2015.10.003>
 23. Jeong K, Kim M, Jeon SA, Kim YH, Lee S. A randomized trial of *Lactobacillus rhamnosus* IDCC 3201 tyndallizate (RHT3201) for treating atopic dermatitis. *Pediatr Allergy Immunol.* 2020;31(7):783–92.
 24. Yan DC, Hung CH, Sy LB, Lue KH, Shih IH, Yang CY, et al. A randomized, double-blind, placebo-controlled trial assessing the oral administration of a heat-treated *Lactobacillus paracasei* supplement in infants with atopic dermatitis receiving topical corticosteroid therapy. *Skin Pharmacol Physiol.* 2019;32(4):201–11.
 25. Ahn SH, Yoon W, Lee SY, Shin HS, Lim MY, Nam Y Do, et al. Effects of *Lactobacillus pentosus* in children with allergen-sensitized atopic dermatitis. *J Korean Med Sci.* 2020;35(18):1–14.
 26. Wang IJ, Wang JY. Children with atopic dermatitis show clinical improvement after *Lactobacillus* exposure. *Clin Exp Allergy.* 2015;45(4):779–87.
 27. Navarro-Lopez V, Ramirez-Bosca A, Ramon-Vidal D, Ruzafa-Costas B, Genoves-Martinez S, Chenoll-Cuadros E, et al. Effect of oral administration of a mixture of probiotic strains on SCORAD index and use of topical steroids in young patients with moderate atopic dermatitis a randomized clinical trial. *JAMA Dermatology.* 2018;154(1):37–43.
 28. Cukrowska B, Ceregra A, Maciorkowska E, Surowska B, Zegadło-Mylik MA, Konopka E, et al. The effectiveness of probiotic *Lactobacillus rhamnosus* and *Lactobacillus casei* strains in children with atopic dermatitis and cow's milk protein allergy: A multicenter, randomized, double blind, placebo controlled study. *Nutrients.* 2021;13(4).
 29. Wickens K, Black P, Stanley T V., Mitchell E, Barthow C, Fitzharris P, et al. A protective effect of *Lactobacillus rhamnosus* HN001 against eczema in the first 2 years of life persists to age 4 years. *Clin Exp Allergy.* 2012;42(7):1071–9.
 30. Enomoto T, Sowa M, Nishimori K, Shimazu S, Yoshida A, Yamada K, et al. Effects of bifidobacterial supplementation to pregnant women and infants in the prevention of allergy development in infants and on fecal microbiota. *Allergol Int [Internet].* 2014;63(4):575–85. Available from: <http://dx.doi.org/10.2332/allergolint.13-OA-0683>
 31. Marlow G, Han DY, Wickens K, Stanley T, Crane J, Mitchell EA, et al. Differential effects of two probiotics on the risks of eczema and atopy associated with single nucleotide polymorphisms to Toll-like receptors. *Pediatr Allergy Immunol.* 2015;26(3):262–71.
 32. Han Y, Kim B, Ban J, Lee J, Kim BJ, Choi BS, et al. A randomized trial of

- Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis. *Pediatr Allergy Immunol.* 2012;23(7):667–73.
33. RØ, Anne Dorthea Bjerkenes, Melanie Rae Simpson, Torstein Baade RØ, Ola Storrø, Roar Johnsen, Vibeke Videm TØ. Reduced Th22 cell proportion of atopic dermatitis in infants following maternal probiotic supplementation. *Int J Lab Hematol.* 2017;47(8):1014–21.

Conflict of Interest Statement:

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2024 NMSJ. All rights reserved.